摘要
多发性骨髓瘤(MM)是不可治愈的血浆细胞瘤,占所有血液恶性肿瘤的约10%。最近,新出现的证据表明MM细胞和浸润性免疫细胞之间的骨髓相互作用的复杂性已被报道可促进肿瘤细胞的增殖,存活和耐药性。微小RNA(miRNA)是在细胞中具有调节功能的小的非编码RNA分子,其表达在不同恶性肿瘤中具有预测和预后价值。由于它们通过不同机制使免疫反应极化的能力,包括免疫细胞的分子重编程,MiRNA正在越来越受到关注。这一特征与miRNA模拟物或抑制剂的抗肿瘤活性一起使得miRNA网络成为新型抗MM治疗方法的有吸引力的研究领域。在这篇综述中,我们将讨论MM细胞与骨髓宿主免疫细胞间相互作用的最新进展,特别关注miRNA网络调制引起的分子和功能变化。我们终将指出治疗干预的潜在目标。
关键词: MicroRNA,miRNA,多发性骨髓瘤,免疫治疗,肿瘤免疫学,免疫反应。
图形摘要
Current Cancer Drug Targets
Title:Immunomodulatory Activity of MicroRNAs: Potential Implications for Multiple Myeloma Treatment
Volume: 17 Issue: 9
关键词: MicroRNA,miRNA,多发性骨髓瘤,免疫治疗,肿瘤免疫学,免疫反应。
摘要: Multiple myeloma (MM) is an incurable plasma cell neoplasm accounting for about 10% of all hematologic malignancies. Recently, emerging evidence is disclosing the complexity of bone marrow interactions between MM cells and infiltrating immune cells, which have been reported to promote proliferation, survival and drug resistance of tumor cells. MicroRNAs (miRNAs) are small non-coding RNA molecules with regulatory functions in the cell, whose expression has predictive and prognostic value in different malignancies. MiRNAs are gaining increasing interest due to their capability to polarize the immune-response through different mechanisms, which include the molecular reprogramming of immune cells. This characteristic, together with the antitumor activity of miRNA mimics or inhibitors, make the miRNA network an attractive area of investigation for novel anti-MM therapeutic approaches. In this review, we will discuss the recent advances in the understanding of the interplay between MM cells and bone marrow resident immune cells, with special focus on the molecular and functional changes induced by miRNA network modulation. We will finally indicate potential targets for therapeutic intervention.
Export Options
About this article
Cite this article as:
Immunomodulatory Activity of MicroRNAs: Potential Implications for Multiple Myeloma Treatment, Current Cancer Drug Targets 2017; 17 (9) . https://dx.doi.org/10.2174/1568009617666170330154756
DOI https://dx.doi.org/10.2174/1568009617666170330154756 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The MDM2 Inhibitor Nutlins as an Innovative Therapeutic Tool for the Treatment of Haematological Malignancies
Current Pharmaceutical Design Intracoronary Injection of Drugs to Treat No – Reflow Phenomenon and Microcirculatory Dysfunction
Cardiovascular & Hematological Agents in Medicinal Chemistry Recent Advances in the Imaging of Programmed Cell Death
Current Pharmaceutical Design Biological and Clinical Significance of Polymorphisms in NAD(P)H: Quinone Oxidoreductase 1 (NQO1)
Current Pharmacogenomics Advances in Transient Receptor Potential Vanilloid-2 Channel Expression and Function in Tumor Growth and Progression
Current Protein & Peptide Science Targeted Drugs in Chronic Myeloid Leukemia
Current Medicinal Chemistry Radionuclide Therapy of Cancer with Radiolabeled Antibodies
Anti-Cancer Agents in Medicinal Chemistry Medical Systemic Therapies for Hepatocellular Carcinoma: Clinical Perspectives and Safety Profile
Current Drug Safety Progress in the Diagnosis and Treatment of Pulmonary Aspergillosis
Current Respiratory Medicine Reviews Medication-Induced Nephrotoxicity in Older Patients
Current Drug Metabolism Pharmacokinetics, Pharmacodynamics and Clinical Use of Valganciclovir in Newborns with Symptomatic Congenital Cytomegalovirus Infection
Current Drug Metabolism A Very Rare Cerebral Complication of Chemotherapy in a Young Girl: A Difficult Diagnosis
Current Drug Safety The Crosstalk Between the Matrix Metalloprotease System and the Chemokine Network in Acute Myeloid Leukemia
Current Medicinal Chemistry Targeted Therapies in Non-Small Cell Lung Cancer: Proven Concepts and Unfulfilled Promises.
Current Cancer Drug Targets Acute Lymphoblastic Leukemia and Regulatory T cells: Biomarkers and Immunopathogenesis
Current Immunology Reviews (Discontinued) CEBP Epigenetic Dysregulation as a Drug Target for the Treatment of Hematologic and Gynecologic Malignancies
Current Drug Targets Unexpected High Levels of Vorinostat when Combined with Vinorelbine in Patients with Advanced Cancer
Current Clinical Pharmacology Structure Based Lead Optimization Approach in Discovery of Selective DPP4 Inhibitors
Mini-Reviews in Medicinal Chemistry Current Advances in Retroviral Gene Therapy
Current Gene Therapy Editorial [Hot Topic: Mammalian Target of Rapamycin as a Therapeutic Target in Leukemia (Executive Editors: Francis J. Giles / Maher Albitar)]
Current Molecular Medicine